Table 2.
Supplements effect on maternal and fetal outcomes
| Maternal Outcomes | Foetal Outcomes | ||||
|---|---|---|---|---|---|
| GDM Diagnosis | Metabolic Outcomes | Birth Weight | Hypoglycaemic Episodes | Respiratory Distress Syndrome | |
| Myo‐inositol (4000 mg/die)a | ↓ | Improved | ↓ | ↓ | No data available |
| d‐chiro inositol (>500 mg/die)a | ‐ | Improved | ‐ | ‐ | No data available |
| α‐Lipoic acid | No data available | Improved | No data available | No data available | No data available |
| Resveratrol | No data available | ‐ | No data available | No data available | No data available |
| Epigallocatechin 3‐gallate | No data available | Improved | ↓ | ↓ | ↓ |
Note. Cells with “‐” represent inconsistent data.
a
Period of treatment more than 8 weeks.